Carcinoid syndrome is a collection of symptoms caused by hormones and other substances released by slow-growing tumors called neuroendocrine tumors (NETs), most often after those tumors have spread to the liver. The hallmark symptoms are flushing of the skin, persistent diarrhea, abdominal cramping, and sometimes wheezing. Only a minority of people with neuroendocrine tumors develop the syndrome, because the liver normally breaks down the tumor’s secretions before they reach the rest of the body. Once tumor cells set up shop inside the liver itself, their chemical output drains directly into the bloodstream and triggers widespread effects that can range from mildly annoying to life-threatening.
Why Liver Spread Is the Trigger
Neuroendocrine tumors most commonly originate in the small intestine, though they can also arise in the lungs, stomach, appendix, and other organs. Even when these tumors are actively secreting hormones, the portal vein routes that output through the liver first, where enzymes neutralize most of it. Carcinoid syndrome typically appears only after the tumor has metastasized to the liver, because liver metastases release their products directly into the hepatic veins and then into systemic circulation. Liver metastases are considered the main cause of carcinoid syndrome and, over time, can lead to liver dysfunction, heart failure, and death.1BioMed Central / Europe PMC. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy One exception worth knowing: tumors originating in the lungs or ovaries can sometimes cause the syndrome without liver involvement, because their venous drainage bypasses the portal system entirely.
The Chemical Culprits Behind the Symptoms
Serotonin gets most of the attention, but carcinoid syndrome is driven by a cocktail of substances. The tumors can release serotonin, tachykinins (a family of small signaling molecules), histamine, catecholamines, and other vasoactive compounds.2PubMed Central. What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators Which mediator does what has been debated for decades. For diarrhea, the case for serotonin is strong: excess serotonin speeds up the contractions that move food through the gut, reducing the intestine’s ability to absorb water and electrolytes.3PubMed Central. Management of Diarrhea in Patients With Carcinoid Syndrome
Flushing is more complicated. Studies measuring serotonin levels during flushing episodes have produced contradictory results, while tachykinin levels tend to rise more consistently during flushes. Tachykinins have even been linked to the diarrhea component, suggesting they play a broader role than originally thought.4PubMed Central. What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators Bradykinin, once a popular suspect for the flushing, appears to be a dead end: one study found that blood bradykinin levels were normal in all patients tested and concluded it is unlikely to be the vasoactive mediator of flushing.5Gut. Bradykinin in carcinoid syndrome The honest summary is that flushing probably results from several mediators acting together, and the relative contribution of each varies from patient to patient.
What the Symptoms Feel Like
The classic triad is flushing, diarrhea, and wheezing, though not everyone gets all three. Flushing typically involves the face and upper chest, lasts anywhere from a few minutes to half an hour, and can be triggered by alcohol, stress, certain foods, or physical exertion. Unlike a hot flash during menopause, carcinoid flushing often has a purplish or deep-red hue and can become more severe as the disease progresses.
Diarrhea is the symptom that tends to grind people down. It is often watery, can strike many times a day, and does not always coincide with flushing episodes. Because serotonin is the primary driver of the diarrhea, treatments that lower serotonin production or block its effects tend to help this symptom more predictably than they help flushing.6PubMed Central. Management of Diarrhea in Patients With Carcinoid Syndrome Wheezing and abdominal pain round out the picture but are less common. Wheezing results from bronchospasm triggered by the same circulating mediators, and it can occasionally be mistaken for asthma.
Carcinoid Heart Disease
One of the most serious long-term consequences is damage to the heart valves. Serotonin and its metabolites promote the growth of fibrous plaques on the inside surfaces of the heart, particularly on the right side. These plaques thicken and stiffen the tricuspid and pulmonary valves, leading to regurgitation (leaking) or stenosis (narrowing). In one study of 19 patients, tricuspid regurgitation was found in every single patient on echocardiography, and the data pointed strongly toward serotonin as the driving force behind the plaque formation.7PubMed. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography Animal research has confirmed the connection: rats given serotonin over an extended period developed thickened valve cusps with plaque resembling what is seen in human carcinoid heart disease.8PubMed. Long-term serotonin administration induces heart valve disease in rats
The right side of the heart takes the brunt because blood carrying tumor-derived serotonin passes through the right heart chambers before reaching the lungs, where enzymes break most of it down. Left-sided valve disease can occur but is much rarer and tends to appear in patients with very high serotonin levels, a lung-origin tumor, or a cardiac defect that allows blood to cross from the right side to the left without passing through the lungs. Because carcinoid heart disease can progress silently, regular echocardiograms are a standard part of monitoring.
Niacin Deficiency and Pellagra
Here is a consequence that catches many people off guard. The amino acid tryptophan is the raw material for both serotonin and niacin (vitamin B3). Normally, serotonin production uses only a small fraction of available tryptophan, leaving plenty for niacin synthesis. When a neuroendocrine tumor hijacks tryptophan to churn out excess serotonin, the niacin pathway gets starved.9PubMed. Biochemical assessment of niacin deficiency among carcinoid cancer patients The result can be pellagra, a condition classically associated with severe malnutrition, marked by dermatitis, diarrhea, and dementia.
In carcinoid patients, pellagra does not always look textbook. A case report described a patient with a pulmonary carcinoid tumor who developed a subtle rash on the hands and feet rather than the classic sun-exposed distribution.10PubMed Central. Pellagra From Tryptophan Depletion in Carcinoid Syndrome due to a Pulmonary Atypical Carcinoid Neuroendocrine Tumor Because the presentation can be atypical, clinicians are advised to suspect niacin deficiency in any NET patient with chronic diarrhea and new skin changes and to consider starting niacin supplementation even before lab results come back.
Cognitive and Psychiatric Effects
Serotonin is one of the brain’s most important signaling chemicals, so it is not surprising that carcinoid syndrome can affect mental function. A scoping review identified reports of mood disturbances, depression, anxiety, psychosis, impulse-control problems, and sleep disruption among NET patients.11PubMed. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review More focused research found that about one in nine patients with serotonin-producing NETs tested as cognitively impaired, with attention deficits being the most common domain affected. Roughly one in five received a psychiatric diagnosis, most often adjustment disorder with depressed or anxious mood.12Translational Psychiatry. Psychiatric and cognitive function in patients with serotonin producing neuroendocrine tumors
Interestingly, the cognitive picture is not uniformly negative. In a small study comparing patients with proven carcinoid syndrome to matched healthy controls, patients had lower tryptophan levels and impaired sustained visual attention, but they actually performed better at learning new associations between stimuli and responses.13PubMed. Neuropsychological investigation into the carcinoid syndrome The finding is unusual and not fully explained, but it underscores that serotonin disturbances do not simply cause global brain impairment. Different cognitive functions are affected in different directions.
How Carcinoid Syndrome Is Diagnosed
When a doctor suspects carcinoid syndrome, the first step is usually measuring 5-hydroxyindoleacetic acid (5-HIAA), the main breakdown product of serotonin, in a 24-hour urine collection. Elevated 5-HIAA is a reliable marker of serotonin overproduction and correlates with symptom severity. The rate at which 5-HIAA levels rise over time also carries prognostic information: in patients with small-intestine NETs, a faster doubling time was associated with a higher risk of disease progression.14PubMed Central. Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients with Neuroendocrine Tumors Certain foods rich in serotonin, like bananas, avocados, walnuts, and pineapples, can falsely elevate the result, so patients are typically told to avoid these before collection.
Locating the tumor and its metastases often requires specialized imaging. Neuroendocrine tumors can be small and hard to spot on standard CT or MRI scans. A newer approach uses a radioactive tracer called 68-Gallium DOTATATE, which binds to receptors that NETs express on their surfaces, making even tiny tumors light up on a PET-CT scan.15PubMed Central. Use of 68Ga DOTATATE, a new molecular imaging agent, for neuroendocrine tumors This scan has proven especially useful in patients who have clear symptoms but whose conventional imaging comes back clean: it can detect tumors that anatomical scans miss entirely and change the treatment plan as a result.16PubMed Central. 68-Gallium DOTATATE scanning in symptomatic patients with negative anatomic imaging but suspected neuroendocrine tumor
First-Line Medical Treatment
Somatostatin analogs, synthetic versions of a hormone that dials down the secretion of many other hormones, are the backbone of symptom control. Octreotide and lanreotide are the two most widely used. They work by binding to receptors on the tumor cells and reducing the release of serotonin and other mediators. In patients who had never received a somatostatin analog before, lanreotide reduced the percentage of days with moderate or severe diarrhea and flushing compared to placebo.17PubMed. Lanreotide therapy in carcinoid syndrome: prospective analysis of patient-reported symptoms in patients responsive to prior octreotide therapy and patients naïve to somatostatin analogue therapy in the ELECT phase 3 study Most patients respond well at first, but symptoms can break through over time as the tumor grows or adapts.
When somatostatin analogs are no longer enough to control diarrhea, telotristat ethyl can be added. This drug works differently: it blocks tryptophan hydroxylase, the enzyme that converts tryptophan into serotonin, choking off serotonin production at the source. In a phase 3 trial (TELESTAR), patients still having four or more bowel movements per day on somatostatin analogs saw their daily bowel movements drop by about 1.7 on the 250 mg dose, compared to a 0.9 drop on placebo. Roughly 44% of those on telotristat ethyl had a durable response, versus 20% on placebo.18PubMed. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome A second trial (TELECAST), which included patients with fewer daily bowel movements, confirmed similar reductions in urinary 5-HIAA and bowel movement frequency, supporting the drug’s safety and efficacy across a broader range of patients.19PubMed Central. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Radionuclide Therapy and Liver-Directed Treatments
For patients whose symptoms remain poorly controlled, peptide receptor radionuclide therapy (PRRT) is an option. This treatment uses a radioactive compound, 177Lu-DOTATATE, that homes in on the same somatostatin receptors the diagnostic scan targets, delivering targeted radiation directly to tumor cells. In a study of patients with refractory carcinoid syndrome, PRRT reduced both diarrhea and flushing. Among patients who started with four or more bowel movements per day, nearly half achieved at least a 30% reduction, and two-thirds of those with frequent flushing saw their daily episodes drop by more than half.20The Journal of Clinical Endocrinology & Metabolism. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
Because liver metastases are the primary fuel for the syndrome, treatments aimed directly at the liver can make a dramatic difference. Hepatic artery embolization, which blocks the blood supply feeding the tumors, achieved a symptomatic response in about 87% of patients in one long-running series, with a median response lasting at least 11 months.21PubMed. The carcinoid syndrome: palliation by hepatic artery embolization Surgical removal of liver metastases (cytoreduction) is another strategy. In a comparison of the two approaches, patients who underwent cytoreduction enjoyed a longer symptom-free interval, averaging about 35 months versus 22 months for embolization.22PubMed. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors A more recent analysis comparing surgical debulking to non-surgical management found that about 90% of surgical patients reported symptom improvement, and their median symptom-free interval was roughly 28 months compared to about 16 months for those managed with medications and liver-directed therapy alone.23Journal of Clinical Oncology. Surgical debulking versus non-surgical management for the control of carcinoid syndrome in metastatic small bowel neuroendocrine tumors Not every patient is a surgical candidate, though, and these procedures carry their own risks.
Carcinoid Crisis
Perhaps the most dangerous acute complication is carcinoid crisis, a sudden, massive release of hormones that can cause wild swings in blood pressure (usually a severe drop), prolonged flushing, high fever, and bronchospasm. It can be triggered by surgery, anesthesia, tumor manipulation during a procedure, arterial embolization, emotional stress, or even diagnostic endoscopy. Patients with large tumors, high 5-HIAA levels, or existing carcinoid heart disease face the highest risk.24Neuroendocrinology. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors
Intravenous octreotide is the mainstay for both preventing and treating carcinoid crisis. Patients at risk are typically started on an octreotide infusion before any procedure and kept on it throughout. Managing the blood-pressure swings is tricky because standard vasopressors that boost catecholamine activity can paradoxically worsen the crisis by stimulating further hormone release from the tumor. Some centers have used catecholamines successfully for right-heart support during cardiac surgery, but the practice remains controversial and case-by-case.25PubMed Central. Balancing carcinoid crisis and right ventricular dysfunction during tricuspid and pulmonic valve replacement for carcinoid heart disease: A case report
Conditions That Mimic the Syndrome
Flushing is common and has a long list of causes, most of them benign. Menopause, rosacea, alcohol intolerance, certain medications, anxiety, and even spicy food can all produce flushing that might superficially resemble carcinoid syndrome. Among endocrine causes specifically, the differential includes pheochromocytoma, medullary thyroid cancer, and certain pancreatic neuroendocrine tumors, each of which involves different hormones and different patterns of flushing. What tends to distinguish carcinoid flushing is the combination of flushing with chronic watery diarrhea and an elevated 5-HIAA on urine testing. Someone who flushes but has normal bowel habits and normal urinary 5-HIAA almost certainly does not have carcinoid syndrome.
Genetic Syndromes and Familial Risk
Most neuroendocrine tumors arise sporadically, without a family connection. However, at least eight inherited syndromes have been identified that increase the risk of developing endocrine tumors, the most well known being multiple endocrine neoplasia type 1 (MEN1) and type 2 (MEN2). MEN1 in particular predisposes people to NETs of the pancreas, and less commonly the lungs or thymus. Having a family member with MEN1 does not mean you will develop carcinoid syndrome, but it does mean screening for neuroendocrine tumors should be part of routine care. Genetic counseling can clarify individual risk.
How the Name Came About
The word “carcinoid” has an odd history. In 1907, a German pathologist named Siegfried Oberndorfer was studying small tumors in the intestine that several earlier researchers had noticed but never properly categorized. He recognized them as a distinct type and called them “karzinoide,” meaning “carcinoma-like,” to emphasize that they looked like cancers under the microscope but behaved far more gently than typical malignancies.26PubMed. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors Twenty-two years later, in 1929, Oberndorfer revised his view to acknowledge that these tumors could in fact become malignant and spread.27JAMA Surgery. Siegfried Oberndorfer and the Evolution of Carcinoid Disease The name stuck even as understanding of the tumors evolved, and today “carcinoid” is gradually being replaced in medical literature by the broader term “neuroendocrine tumor.” But “carcinoid syndrome” remains firmly entrenched as the name for the hormonal havoc these tumors can cause.